retatrutide what is retatrutide clinical trial Reta data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP GLP-3 Retatrutide · Disguised Alpha

This is where strategic meal planning becomes essential

Tesamorelin counteracts this tendency through growth hormone elevation

The best electrolytes for GLP-1 users replace what exercise depletes without adding excessive sugar that feeds oral bacteria

But how do these drugs compare, and which one might be best for you

Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver

Anticipated retatrutide uses Obesity In the phase 2 trial of retatrutide published in the New England Journal of Medicine (NEJM), a group of 338 adults with obesity were randomly given either a placebo or one of four different doses of retatrutide: 1 mg, 4 mg, 8 mg, or 12 mg